Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Inks Deal With TGen for Skin Cancer Genetics

NEW YORK, Aug. 31 (GenomeWeb News) - Sequenom will provide the Translational Genomics Research Institute access to its candidate gene portfolio of targets associated with and individual's predisposition for skin cancer, the company announced today.

 

Under the terms of the agreement, TGen will further validate the candidate genes against its expression databases with regard to their potential use as diagnostic markers for skin cancer risk and for the clinical prognosis of skin cancer patients. Any products resulting from the collaboration will be jointly owned and commercialized, Sequenom said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more